respectively, an estimated mean (95% CI) difference of −45.9%
(−52.5% to −39.3%) (P b .0001). Low-density lipoprotein cholesterol b70 mg/dL was achieved by 75% alirocumab versus 9%
placebo patients at week 24. At week 12, 83.2% of evaluable alirocumab-treated patients remained on 75-mg Q2W.
Treatment-emergent adverse events were comparable between groups.